Related Experiment Videos
[Selective estrogen-receptor modulators (SERM's) in postmenopausal women]
1Academisch Ziekenhuis Vrije Universiteit, afd. Endocrinologie, Amsterdam.
Nederlands Tijdschrift Voor Geneeskunde
|September 24, 1999
Summary
Selective oestrogen receptor modulators (SERMs) offer benefits for postmenopausal women, improving bone density and reducing fracture risk. Unlike estrogen therapy, SERMs also lower the risk of breast cancer, with raloxifene showing promise for osteoporosis treatment.
Area of Science:
- Pharmacology and Endocrinology
- Oncology
- Bone Metabolism
Context:
- Selective estrogen receptor modulators (SERMs) represent a novel drug class with tissue-specific estrogenic or anti-estrogenic effects.
- Postmenopausal women are a key demographic for SERM application due to hormonal changes and associated health risks.
Purpose:
- To review the current understanding and applications of SERMs in postmenopausal women.
- To compare the effects of different SERMs, specifically tamoxifen and raloxifene, on various health outcomes.
Summary:
- SERMs positively influence lipoprotein cholesterol and bone mineral density in postmenopausal women, reducing vertebral fracture risk.
- SERMs decrease the risk of mammary carcinoma, offering an advantage over traditional estrogen therapy.
- Tamoxifen is associated with increased endometrial hyperplasia and carcinoma risk, whereas raloxifene inhibits uterine proliferation and is indicated for osteoporosis prevention and treatment.
Impact:
- Raloxifene is emerging as a significant therapeutic option for osteoporosis in postmenopausal women.
- The long-term impact of SERMs on cardiovascular disease and breast cancer prevention requires further investigation.
- SERMs demonstrate a differentiated profile compared to estrogen therapy, particularly concerning endometrial and breast tissue effects.